Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2021

Feb 07, 2022

SELL
$198.88 - $227.6 $1.28 Million - $1.46 Million
-6,426 Closed
0 $0
Q3 2021

Dec 02, 2021

BUY
$212.27 - $248.7 $43,939 - $51,480
207 Added 3.33%
6,426 $1.37 Million
Q1 2021

May 04, 2021

BUY
$221.91 - $258.6 $8,654 - $10,085
39 Added 0.63%
6,219 $1.55 Million
Q4 2020

Feb 02, 2021

SELL
$216.38 - $257.67 $22,070 - $26,282
-102 Reduced 1.62%
6,180 $1.42 Million
Q3 2020

Oct 29, 2020

SELL
$234.65 - $260.95 $51,857 - $57,669
-221 Reduced 3.4%
6,282 $1.6 Million
Q2 2020

Aug 06, 2020

SELL
$197.81 - $242.74 $74,376 - $91,270
-376 Reduced 5.47%
6,503 $1.53 Million
Q1 2020

Apr 06, 2020

SELL
$182.24 - $241.7 $10,387 - $13,776
-57 Reduced 0.82%
6,879 $1.4 Million
Q4 2019

Jan 07, 2020

SELL
$189.21 - $243.2 $22,705 - $29,184
-120 Reduced 1.7%
6,936 $1.67 Million
Q3 2019

Oct 11, 2019

SELL
$174.11 - $208.62 $16,366 - $19,610
-94 Reduced 1.31%
7,056 $1.37 Million
Q2 2019

Jul 24, 2019

BUY
$166.7 - $195.41 $2,667 - $3,126
16 Added 0.22%
7,150 $1.32 Million
Q1 2019

Apr 29, 2019

SELL
$180.87 - $203.88 $45,760 - $51,581
-253 Reduced 3.42%
7,134 $1.36 Million
Q4 2018

Feb 07, 2019

SELL
$178.4 - $208.25 $45,670 - $53,312
-256 Reduced 3.35%
7,387 $1.44 Million
Q3 2018

Oct 30, 2018

SELL
$185.29 - $208.89 $20,196 - $22,769
-109 Reduced 1.41%
7,643 $1.58 Million
Q2 2018

Aug 13, 2018

BUY
$166.05 - $186.51 $37,859 - $42,524
228 Added 3.03%
7,752 $1.43 Million
Q1 2018

May 08, 2018

SELL
$169.43 - $198.0 $677 - $792
-4 Reduced 0.05%
7,524 $1.28 Million
Q4 2017

Mar 27, 2018

BUY
$168.79 - $188.59 $1.27 Million - $1.42 Million
7,528
7,528 $1.31 Million

Others Institutions Holding AMGN

About AMGEN INC


  • Ticker AMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 534,931,008
  • Market Cap $171B
  • Description
  • Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces th...
More about AMGN
Track This Portfolio

Track Claret Asset Management Corp Portfolio

Follow Claret Asset Management Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Claret Asset Management Corp, based on Form 13F filings with the SEC.

News

Stay updated on Claret Asset Management Corp with notifications on news.